Treatment of hepatitis C

Summary.  The combination of pegylated interferon alpha and ribavirin has improved treatment success rates in patients with hepatitis C with sustained response rates of just over 50% overall and more than 70% for those with genotypes 2 and 3. This article reviews the use of combination therapy, contraindications, factors influencing response and describes approaches to specific patient groups.

[1]  U. Neumann,et al.  Discussion on spontaneous resolution of chronic hepatitis C virus after withdrawal of immunosuppression. , 2004, Gastroenterology.

[2]  Murray Krahn,et al.  Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  J. Gisbert,et al.  Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. , 2003, Gastroenterology.

[4]  Kholoud Porter,et al.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.

[5]  T. Berg,et al.  Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C , 2003 .

[6]  P. Roderick,et al.  Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy , 2003, Gut.

[7]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[8]  X. Forns,et al.  Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. , 2003, Journal of hepatology.

[9]  R. Gilroy,et al.  Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation , 2003, American Journal of Gastroenterology.

[10]  G. Tomlinson,et al.  High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C , 2003, Hepatology.

[11]  F. Nevens,et al.  Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378] , 2003, BMC gastroenterology.

[12]  D. Dieterich,et al.  Hematologic disorders associated with hepatitis C virus infection and their management. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  S. Gawrieh,et al.  Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. , 2003, Gastroenterology.

[14]  G. Tomlinson,et al.  Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[15]  A. Bruchfeld,et al.  Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  M. Manns,et al.  Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.

[17]  N. Gruener,et al.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.

[18]  Samir K. Gupta,et al.  Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. , 2003, British journal of clinical pharmacology.

[19]  A. Perelson,et al.  Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin , 2003, Hepatology.

[20]  B. Walker,et al.  Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. , 2003, Gastroenterology.

[21]  M. Muscaritoli,et al.  Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. , 2003, Journal of nephrology.

[22]  R. Ceriani,et al.  Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. , 2003, Journal of hepatology.

[23]  P. Heagerty,et al.  Racial differences in the relationship between hepatitis C infection and iron stores , 2003, Hepatology.

[24]  J. Albrecht,et al.  Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. , 2003, Gastroenterology.

[25]  R. Roldán,et al.  Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Sulkowski,et al.  Hepatitis C in the HIV-Infected Person , 2003, Annals of Internal Medicine.

[27]  T. Hammett.  Adopting More Systematic Approaches to Hepatitis C Treatment in Correctional Facilities , 2003, Annals of Internal Medicine.

[28]  H. Grunze,et al.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.

[29]  E. Penner,et al.  Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load , 2003, Hepatology.

[30]  A. Sherker,et al.  Treatment of transfusion‐dependent thalassemic patients infected with hepatitis C virus with interferon α‐2b and ribavirin , 2003 .

[31]  J. Piette,et al.  Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. , 2002, Arthritis and rheumatism.

[32]  M. Fried,et al.  Side effects of therapy of hepatitis C and their management , 2002, Hepatology.

[33]  J. Hoofnagle,et al.  Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C , 2002, Hepatology.

[34]  S. Wirth,et al.  Recombinant alfa‐interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C , 2002, Hepatology.

[35]  A. Pittenger,et al.  Single‐Dose Pharmacokinetics and Safety of Pegylated Interferon‐α2b in Patients with Chronic Renal Dysfunction , 2002, Journal of clinical pharmacology.

[36]  M. Sata,et al.  Interferon therapy prolonged life expectancy among chronic hepatitis C patients. , 2002, Gastroenterology.

[37]  D. Guyader,et al.  Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. , 2002, Journal of hepatology.

[38]  M. Rizzetto,et al.  Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. , 2002, Journal of hepatology.

[39]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[40]  D. Purdie,et al.  Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C , 2002, Gut.

[41]  D. Sylvestre.  Treating hepatitis C in methadone maintenance patients: an interim analysis. , 2002, Drug and alcohol dependence.

[42]  S. Ha,et al.  Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major , 2002, British journal of haematology.

[43]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[44]  G. Barbarini,et al.  Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study , 2002, European journal of gastroenterology & hepatology.

[45]  N. Martin,et al.  Weight-Based versus Fixed Dosing of Peginterferon (40kDa) Alfa-2a , 2002, The Annals of pharmacotherapy.

[46]  D. Vlahov,et al.  Protection against persistence of hepatitis C , 2002, The Lancet.

[47]  Angelo Balestrieri,et al.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Wiley,et al.  Hepatitis C infection in African Americans: its natural history and histological progression , 2002, American Journal of Gastroenterology.

[49]  K. Bjøro,et al.  Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up , 2002, European Addiction Research.

[50]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[51]  A. Andriulli,et al.  Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data , 2001, Gut.

[52]  P. Marcellin,et al.  Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA , 2001, Hepatology.

[53]  G. Davis,et al.  Treatment of chronic hepatitis C in active drug users. , 2001, The New England journal of medicine.

[54]  K. Seal,et al.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? , 2001, The New England journal of medicine.

[55]  S. Hadziyannis,et al.  Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.

[56]  P. Andreone,et al.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. , 2001, Journal of hepatology.

[57]  I. Wanless,et al.  High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C , 2001 .

[58]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[59]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  S. Goodman,et al.  Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.

[61]  J. Wong,et al.  Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta‐analysis of controlled and uncontrolled trials , 2001, Hepatology.

[62]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[63]  J. Albrecht,et al.  The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. , 2000, Gastroenterology.

[64]  J. Hoofnagle,et al.  Hepatitis C in African Americans: summary of a workshop. , 2000, Gastroenterology.

[65]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[66]  A. D. Di Bisceglie.  Natural history of hepatitis C: Its impact on clinical management , 2000, Hepatology.

[67]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.

[68]  M. Repanti,et al.  Response to Interferon Alfa-2b Therapy in Multitransfused Children with Beta-thalassemia and Chronic Hepatitis C , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[69]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[70]  O. Weiland,et al.  Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. , 1999, Gastroenterology.

[71]  E. Kenny‐Walsh.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.

[72]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[73]  B. Portmann,et al.  A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation , 1998, Hepatology.

[74]  O. Chazouilleres,et al.  Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.

[75]  M. Sherman,et al.  Screening for hepatocellular carcinoma , 1998, Hepatology.

[76]  P. Marcellin,et al.  Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.

[77]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[78]  J. Garson,et al.  Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients , 1997, British journal of haematology.

[79]  K. Fujiwara,et al.  Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. , 1996, The American journal of gastroenterology.

[80]  A. Fauci,et al.  Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. , 1989, The New England journal of medicine.

[81]  H. Conjeevaram,et al.  Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C , 2004, Digestive Diseases and Sciences.

[82]  N. Izumi,et al.  Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. , 2003, General hospital psychiatry.

[83]  E. Mizukoshi,et al.  57 HCV exposure in humans: stimulation of cellular, but not humoral immune responses in the absence of detectable viremia , 2003 .

[84]  G. Foster,et al.  189 Treatment of chronic hepatitis C with peginterferon ALFA-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response , 2003 .

[85]  E. Herrmann,et al.  Pharmacokinetics of Peginterferons , 2003, Seminars in liver disease.

[86]  T. Berg,et al.  Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. , 2003, Journal of hepatology.

[87]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[88]  P. Bonis.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. , 1999, The New England journal of medicine.

[89]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .